CSPI garlic petition denied
This article was originally published in The Tan Sheet
Executive Summary
Center for Science in the Public Interest's citizen petition calling for a halt to "misleading" ad claims linking garlic supplements to lower cholesterol levels denied by FDA in recent letter. Citizen petitions are "not the appropriate vehicle to seek enforcement action," agency contends. However, FDA notes it will "review the information contained in your petition about particular products and claims" and consider whether a violation of the FD&C Act has occurred. CSPI submitted the petition to FDA almost two years ago (1"The Tan Sheet" Dec. 11, 2000, p. 8)...
You may also be interested in...
Garlic Supplement Cholesterol Claims Halt Sought By CSPI
Advertising claims that garlic supplements lower cholesterol, although literally true, are misleading "since the unsupported implication...is that taking garlic supplements is an effective means of reducing cholesterol levels," the Center for Science in the Public Interest advises FTC in a Dec. 5 petition.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.